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Abstract
Objective
Cardiovascular disease (CVD) risk calculators designed for use in the general population do
not accurately predict the risk of CVD among patients with rheumatoid arthritis (RA), who
are at increased risk of CVD. The process of developing risk prediction models involves
numerous issues. Our goal was to develop a CVD risk calculator for patients with RA.
Methods
Thirteen cohorts of patients with RA originating from 10 different countries (UK, Norway,
Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico) were com-
bined. CVD risk factors and RA characteristics at baseline, in addition to information on
CVD outcomes were collected. Cox models were used to develop a CVD risk calculator,
considering traditional CVD risk factors and RA characteristics. Model performance was
assessed using measures of discrimination and calibration with 10-fold cross-validation.
Results
A total of 5638 RA patients without prior CVD were included (mean age: 55 [SD: 14] years,
76% female). During a mean follow-up of 5.8 years (30139 person years), 389 patients
developed a CVD event. Event rates varied between cohorts, necessitating inclusion of high
and low risk strata in the models. The multivariable analyses revealed 2 risk prediction mod-
els including either a disease activity score including a 28 joint count and erythrocyte sedi-
mentation rate (DAS28ESR) or a health assessment questionnaire (HAQ) along with age,
sex, presence of hypertension, current smoking and ratio of total cholesterol to high-density
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lipoprotein cholesterol. Unfortunately, performance of these models was similar to general
population CVD risk calculators.
Conclusion
Efforts to develop a specific CVD risk calculator for patients with RA yielded 2 potential mod-
els including RA disease characteristics, but neither demonstrated improved performance
compared to risk calculators designed for use in the general population. Challenges encoun-
tered and lessons learned are discussed in detail.
Introduction
Patients with rheumatoid arthritis (RA) have a demonstrated increased risk of cardiovascular
disease (CVD) of 1.5–2 fold compared to their peers without RA [1]. The elevated risk has
been shown to be attributable to both traditional and RA-specific factors. Decision-making
regarding indication for cardio-protective medication is supported by use of various CVD risk
prediction algorithms. However, risk calculators designed for use in the general population do
not accurately estimate the risk of CVD in patients with RA [2, 3].
By using risk prediction models, clinical care decisions are made every day based on the
probability of disease or the probability of future events [4, 5]. The methodology for deriving
and assessing risk calculators has received much attention in the statistical literature [6–10]. In
fact, guidelines for reporting multivariable prediction models have recently been published
[11].
Several attempts have been made to improve CVD risk prediction in patients with RA. The
European League Against Rheumatism (EULAR) advocate to apply a 1.5 multiplier to the cal-
culated risk by the nationally recommended CVD risk algorithm, QRISK2 have included a fac-
tor of 1.4 for patients with RA, and the Expanded cardiovascular Risk Score for RA (ERS-RA),
which is the first published RA specific CVD risk calculator. However, these approaches had
significant limitations [1, 12, 13]. A Trans-Atlantic Cardiovascular Consortium for Rheuma-
toid Arthritis (ATACC-RA) was formed in 2012 with the goal of building a risk calculator that
would accurately predict risk of future CVD among patients with RA. This paper will describe
general challenges involved in development of a risk calculator, and more specifically, bottle-
necks in derivation of a risk calculator to optimize prediction of future CVD in RA patients.
Methods
Study populations
Thirteen cohorts of patients with RA originating from 10 different countries (UK, Norway,
Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico) were combined
for the purpose of developing an RA-specific CVD risk algorithm. Details regarding these
cohorts are located in Table 1, on the consortium website (http://www.atacc-ra.com) and in
previous publications [2, 3, 14–24]. The study was approved by ethical boards/committees at
each center. These included the Mayo Clinic and Olmsted Medical Center Institutional Review
Boards, CMO Arnhem Nijmegen, Dudley Local Research Ethics Committee, Office of the
Oslo University Hospital’s Privacy and Data Protection Officer, Ethics Committee at the Uni-
versity Hospital of Umeå, Harbor-UCLA Institutional Review Board, Laiko Hospital Institu-
tional Review Board (Athens, Greece), Human Research Ethics Committee (Medical) from the
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Table 1. Characteristics of included cohorts.
Center Name/
institution
Origin
cohort
Name of Cohort Cohort type
(population
based vs.
referral)
Type of
cohort
(incident/
Established
Age
(years)
Disease
duration
at
inclusion
Inclusion criteria
for RA
Inclusion
years
End
Follow
up
1 Mayo Clinic,
Olmsted County,
Minnesota
United
States
Population-
based
Incident and
prevalent
54.7
(21,
91)
3.5 (0, 48) 1987 ACR criteria
for RA
2000–
2009
2014
2 Radboud
University
Medical Centre,
Nijmegen
Netherlands Population-
based
Incident 54.8
(17,
87)
0.1 (0, 1) 1987 ACR criteria
for RA and
DMARD naïve
1985–
2011
2011
3 Dudley United
Kingdom
Referral Established 60.1
(26,
89)
12.4 (0,
48)
1987 ACR criteria
for RA
2002–
2008
2011
4 Diakonhjemmet
Hospital, Oslo
Norway The European
Research on
Incapacitating
Diseases and
Social Support:
EURIDISS
Established
in 1991
59.5
(32,
79)
12.2 (10,
15)
2002 2013
The Oslo RA
registry: ORAR
Established
in 1994
58.2
(37,
79)
15.1 (13,
20)
2007 2013
5 Northern
Sweden regional
RA cohort,
Umeå
Sweden Population-
based
Incident 54.2
(18,
87)
0.6 (0,
1.7)
1995–
2003
2008
6 Harbor-UCLA
Medical Center,
Torrance,
California
United
States
Referral Established 53.2
(22,
76)
10.7 (0.2,
37)
2010–
2011
2013
7 Hospital
Universitario
Marque´s de
Valdecilla,
Santander
Spain Referral Established 59.2
(19,
88)
7.8 (0, 40) 2010–
2013
2014
8 Laikon Hospital,
Athens
Greece Referral Established 57.7
(24,
80)
9.4 (0.2,
46)
1987 ACR criteria
for RA
2009–
2012
2013
9 Milpark Hospital
Johannesburg
South Africa Referral Established 53.7
(24,
78)
10.8 (0.2,
56)
1987 ACR criteria
for RA
2001–
2012
2013
10 University of
Manitoba,
Winnipeg
Canada Canadian Early
Arthritis Cohort
New onset 48.6
(21,
79)
1.1 (0,8) At least 1
inflamed joint
2000–
2013
2013
11 Instituto
Nacional de
Ciencias
Me´dicas y
Nutricio´n
Salvador
Zubira´n
Mexico Consecutive
patients seen
at Early
Arthritis
Clinic
New Onset 37.6
(16,
79)
0.4 (0, 1) Symptoms onset
12 months with
no prior
rheumatic
diagnosis except
RA (99% ACR
criteria met)
2004–
2013
2014
12 Brigham &
Women’s
hospital, Boston,
Massachusetts
United
States
Brigham and
Women’s
Rheumatoid
Arthritis
Sequential
Study (BRASS)
Referral Established 55.6
(18,
91)
12.5 (0,
58)
Rheumatologist-
verified RA
diagnosis
2003–
2012
2014
(Continued )
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University of the Witwatersrand in Johannesburg, South Africa, University of Manitoba
Health Research Ethics Board and the Manitoba Health Information Privacy Committee, Eth-
ics Committee of Cantabria for Hospital Universitario de Valdecilla in Santander (Spain),
Comites de E´tica e Investigacio´n del Instituto Nacional de Ciencias Me´dicas y Nutricio´n
Salvador Zubira´n, and Arthritis Center Twente Institutional Review Board. The Mayo Clinic
Institutional Review Board approved the cohort aggregation. Data were anonymized and
aggregated for analyses.
Variable definitions
Outcomes. The primary outcomes were fatal/non-fatal CVD events including acute coro-
nary syndrome (ST-elevation and non-ST elevation myocardial infarction and unstable angina
pectoris), chronic ischemic heart disease (stable angina pectoris), coronary revascularization
(e.g., percutaneous coronary intervention and coronary artery bypass grafting), coronary
death, other cardiovascular death, cerebrovascular events (ischemic cerebrovascular accident
and transient ischemic attack) and peripheral vascular events (with and without revasculariza-
tion procedures, peripheral artery disease). Not included were cases of confirmed cerebral
hemorrhage, non-coronary cardiac death, non-ischemic cardiovascular disease, heart failure
and aortic aneurysm.
Cardiovascular risk factors. Traditional CVD risk factors collected at baseline were: age,
sex, smoking status (current, former, never), systolic and diastolic blood pressure, lipid levels
(total cholesterol [TC], high density lipoprotein cholesterol [HDL-c], low density lipoprotein
cholesterol [LDL-c], triglycerides, and TC:HDL-c ratio), body mass index (BMI), family his-
tory of CVD, diabetes mellitus and hypertension. The use of statins and antihypertensive med-
ications at baseline were also registered.
RA disease characteristics. Clinical characteristics were collected at baseline including
rheumatoid factor (RF) positivity, anti-citrullinated protein antibodies (ACPA) positivity,
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), swollen and tender joint
counts based on 28 joints, patient and physician global visual analog scales (VAS), disease
activity score including 28 joints and ESR (DAS28ESR), RA disease duration and health assess-
ment questionnaire (HAQ) disability index. RF and ACPA were considered positive based on
the tests performed at each center. ACPA testing was lacking in some patients. CRP was not
available from 1 cohort, DAS28ESR was not available from 1 cohort, swollen and tender joint
counts were not available from 2 cohorts, patient global VAS was not available from 4 cohorts,
physician global VAS was not available from 8 cohorts, and HAQ was not available from 3
cohorts. Data were also collected on antirheumatic medication use at baseline including syn-
thetic and biologic disease modifying anti-rheumatic drugs (DMARDs) and corticosteroids.
Table 1. (Continued)
Center Name/
institution
Origin
cohort
Name of Cohort Cohort type
(population
based vs.
referral)
Type of
cohort
(incident/
Established
Age
(years)
Disease
duration
at
inclusion
Inclusion criteria
for RA
Inclusion
years
End
Follow
up
13 Spectrum
Twente,
Enschede
Netherlands Arthritis Cohort
Twente
Cardiovascular
Disease
(ACT-CVD)
Consecutive
patients seen
at a
rheumatic
outpatient
clinic
New onset
and
Established
57.8
(20,
84)
6.8 (0, 53) Rheumatologist-
verified RA
diagnosis
2009–
2011
2012
https://doi.org/10.1371/journal.pone.0174656.t001
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Statistical methods
Data from all cohorts were combined into one database. Patients with a history of CVD prior
to baseline were excluded. Multiple imputation methods were used to impute missing values
for the CVD risk factors using 10 repetitions. Two cohorts were missing a large amount
(~75%) of lipid data, but the lipid data were mostly complete from the other cohorts, so only
20% of the lipid data was missing in the combined database. The missing lipid data were
imputed, but analyses excluding these 2 cohorts were also performed to ensure the imputed
data did not overly influence our results. Log-transformations were used when imputing lipid
levels to avoid bias when computing lipid ratios from imputed data [25]. Descriptive statistics
(means, percentages, etc.) were used to summarize the CVD risk factor and RA disease charac-
teristic data and comparisons across cohorts were performed using chi-square and rank sum
tests. Person-year methods were used to calculate the rate of CVD events for each cohort.
Kaplan-Meier methods were used to plot the rates of development of CVD events during fol-
low-up. Inverse probability weighting was used to adjust the CVD event rates for differences
in CVD risk factors across the cohorts [26].
Cox proportional hazard regression analysis was used to develop the risk calculator model.
Due to heterogeneity in CVD event rates between centers, the Cox models were stratified by
center. To avoid issues with instability of estimates for small centers and to reduce the com-
plexity of the model, centers were grouped into 2 strata (high and low CVD risk) based on
CVD event rates. For patients with long follow-up, follow-up time was truncated at 12 years
after baseline to facilitate accurate prediction of CVD risk at the 10 year time point, as truncat-
ing at ten years would necessitate predicting at the edge of the data and including data well
beyond 10 years could influence the coefficients of the risk factors. Least Absolute Shrinkage
and Selection Operator (LASSO)-penalized Cox regression was used for variable selection of
CV risk factors [27]. Determination of the optimal model was based on cross-validation meth-
ods (using the minimal lambda minus 1 standard error rule to reduce the potential for overfit-
ting). RA disease characteristics were then considered one-by-one for inclusion in the model
following inclusion of the CVD adjustors because many of these measures were missing for 1
or more centers.
Smoothing splines were also used to examine potential non-linear effects of the continuous
risk factors. No significant non-linear effects were noted for the CVD risk factors. Assump-
tions of proportional hazards were checked. Predicted probabilities for CVD were obtained
from the final multivariable model.
Model performance was assessed with measures of discrimination and calibration using
10-fold cross validation. Discrimination was assessed using the concordance statistic (c-statis-
tic) as adapted for the Cox model by Harrell [28]. The c-statistic is analogous to the area under
the receiver operating characteristic (ROC) curve. Calibration was assessed by comparing
observed versus expected events in deciles of predicted risk using goodness-of-fit tests similar
to the Hosmer-Lemeshow test, as well as with standardized incidence ratios (SIR) (which com-
pare the overall observed to predicted number of events) and with calibration plots [10]. Cal-
culated predicted events were transformed to expected events [10]. An SIR>1 indicates that
the observed events are higher than expected, meaning the risk calculator underestimates
actual risk. Conversely, an SIR<1 indicates that the observed events are lower than expected,
meaning that the risk calculator overestimates actual risk.
CVD risk was calculated for the purpose of comparison using risk algorithms designed for
use in the general population, including Framingham risk score (FRS) for general CVD risk,
American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort
Equation, QRISK2 and Systematic COronoary Risk Evaluation (SCORE) [5, 12, 29, 30]. Data
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on heart failure were not available in some cohorts, so the FRS predictions were reduced pro-
portionately based on the fraction of non-heart failure events in the Framingham cohort to
ensure a fair comparison between observed and expected events. For QRISK2, the Townsend
deprivation score, atrial fibrillation and chronic kidney disease were not available in our data,
so CVD risk was calculated using a modified QRISK2 algorithm excluding these variables. The
outcome for SCORE includes only fatal events, which limited our analyses using SCORE due
to the small number of fatal events in our cohort. Reclassification was examined, but the net
reclassification index was not computed, as its use is not recommended when miscalibration
exists, which is the case for centers in our low CVD risk strata [9, 31]. Analyses were per-
formed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R 3.2.0 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Baseline characteristics
A total 5638 RA patients without prior CVD were included (mean age: 55 [SD: 14] years, 76%
female; Table 2). During a mean follow-up of 5.8 years (30139 person years), 389 patients
developed a CVD event. Two cohorts consisted of Hispanics (US/UCLA and Mexico), the rest
were almost exclusively Caucasians. RA disease duration varied by cohort: 4 with early RA (<1
year), 7 established RA (mean 9–13 years) and 2 with both. All demographics, RA disease char-
acteristics and CVD risk factors differed significantly between cohorts (p<0.001 for all).
Primary outcome
CVD event rates varied across countries (range 0.1–1.8%/year) with the lowest observed in
Canada, Mexico and UK and the highest in US, Netherlands, and Sweden (Table 3 and Fig
1A). Adjusting for CVD risk factors to account for the differences between cohorts modified
the CVD event rates, but did not reduce the heterogeneity in CVD event rates across cohorts
(Fig 1B). Due to heterogeneity in CVD event rates between centers, risk calculator models
were stratified by high and low CVD risk center groups with Netherlands (Nijmegen and
Enschede), US (Olmsted and Brigham and Women’s Rheumatoid Arthritis Sequential Study)
and Sweden in the high CVD risk strata and all the other centers in the low CVD risk strata.
Risk model development
The next step of the risk calculator development involved assessment of CVD risk factors.
CVD risk factors considered for inclusion were: age, sex, current smoker, ever smoker, systolic
and diastolic blood pressure measures (in mmHg and log-transformed), lipid measures (TC,
HDL-c, LDL-c, triglycerides, and TC:HDL-c ratio), BMI, family history of CVD, diabetes mel-
litus, history of hypertension, use of anti-hypertensives and use of anti-lipemic medications.
The optimal model based on cross-validation methods included 5 variables (age, sex, presence
of hypertension, current smoker and TC:HDL-c ratio) consistently across all 10 imputation
sets. Inclusion of the presence of hypertension instead of systolic blood pressure was undesir-
able because there is a loss of information in the dichotomous hypertension variable compared
to the continuous blood pressure measure. However, inexplicably, systolic and diastolic blood
pressure values were not significant predictors of CVD events in this RA cohort.
Adjusting for the CVD risk factors, each RA disease characteristics was assessed individu-
ally for potential inclusion in the risk calculator (Table 4). Several RA disease characteristics
were significant predictors of CVD (i.e., DAS28ESR, swollen and tender joint counts, both
patient and physician VAS and HAQ). Several other RA disease related characteristics only
Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis
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approached statistical significance. The multivariable modeling revealed 2 possible risk calcu-
lators including either DAS28ESR or HAQ along with age, sex, presence of hypertension, cur-
rent smoker and TC:HDL-c ratio (Table 5). Additional RA disease characteristics did not add
significantly to these models and non-linear effects were not identified.
Table 2. Descriptive baseline characteristics of 5638 patients with rheumatoid arthritis without prior cardiovascular disease, overall along with
lowest and highest mean/percentage by cohort.
Characteristic Available N Total (N = 5638) Cohort variation
Lowest mean/percentage Highest mean/percentage
Length of follow-up, years 5638 5.8 (4.4) 1.6 9.5
Calendar year of RA diagnosis 5628 1998.4 (9.9) 1990.4 2006.8
Age, years 5685 55.3 (14.0) 37.6 60.1
Sex, female 5638 4278 (76%) 66% 90%
White race 3945 3699 (94%) 63% 100%
CVD risk factors
Systolic blood pressure, mmHg 5345 136.0 (21.9) 115.6 147.6
Diastolic blood pressure, mmHg 5343 79.6 (11.1) 72.0 85.7
Total cholesterol, mmol/L 4457 5.2 (1.1) 4.4 5.7
Low density lipoprotein cholesterol, mmol/L 4364 3.1 (1.0) 2.3 3.9
High density lipoprotein cholesterol, mmol/L 4403 1.5 (0.4) 1.1 1.7
Triglycerides, mmol/L 4240 1.4 (0.8) 1.1 1.7
Current smoker 5368 1148 (21%) 7% 33%
Ever smoker 5120 2688 (52%) 16% 74%
Body mass index, kg/m2 5160 27.0 (5.4) 24.9 29.0
Hypertension 5609 2344 (42%) 9% 67%
Diabetes mellitus 5637 395 (7%) 3% 17%
Family history of CVD 3677 876 (24%) 3% 50%
RA disease characteristics
RA disease duration, years 5628 6.4 (9.2) 0.1 12.9
RF and/or ACPA positive 5485 3949 (72%) 50% 92%
Erythrocyte sedimentation rate, mm/hr 4737 24.8 (21.4) 15.4 32.5
C-reactive protein, mg/L 4528 15.4 (27.1) 2.0 28.3
Severe extra-articular manifestations of RA 4795 262 (6%) 0% 17%
DAS28ESR 4448 4.0 (1.7) 2.5 6.0
Swollen joint count 28 4267 6.3 (6.2) 1.7 13.5
Tender joint count 28 4267 6.2 (6.6) 1.6 13.8
Patient VAS 3851 39.0 (25.7) 31 56
HAQ 3192 0.7 (0.7) 0.2 1.5
Medications
Antihypertensive medication 5608 1314 (23%) 1% 42%
Lipid-lowering medication 5604 510 (9%) 0% 41%
Synthetic DMARD use 5593 2610 (47%) 0% 100%
Biologic DMARD use 5592 891 (16%) 0% 60%
Corticosteroid use 5590 1527 (27%) 8% 73%
Corticosteroid dosage, mg/day 869 5.8 (4.4) 4.5 9.1
Values in table are mean (SD) or n (%). Abbreviations: RA = rheumatoid arthritis, CVD = cardiovascular disease, RF = rheumatoid factor, ACPA = anti-
citrullinated protein antibody, DAS = disease activity score, ESR = erythrocyte sedimentation rate, HAQ = health assessment questionnaire,
DMARD = disease modifying anti-rheumatic drug
https://doi.org/10.1371/journal.pone.0174656.t002
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Model performance
The developed risk calculators demonstrated discrimination that was no better than the estab-
lished risk calculators (c-statistic: 0.71 for FRS, 0.72 for ACC/AHA, 0.70 for SCORE and 0.72
for QRISK2). Ten-fold cross-validation was used to provide an internal validation, and it
revealed c-statistics of 0.70 for Model A and 0.71 for Model B (Table 6). Overall calibration of
the developed risk calculators assessed using ten-fold cross-validation yielded SIR = 0.83 for
both models, indicating that the risk calculator estimates were significantly higher than
observed events. Moderate calibration, assessed according to deciles of predicted risk, was bet-
ter in the developed risk calculators than in the established risk calculators as none of the dec-
iles demonstrated significant differences between observed and predicted risks in the 2 new
risk calculators (Fig 2). In contrast, both the FRS and the ACC/AHA underestimated CVD
risk in the highest decile of predicted risk. The ACC/AHA also overestimated CVD risk in sev-
eral other deciles of predicted risk. SCORE was not depicted because the smaller number of
fatal events in our cohort made it difficult to assess deciles of predicted risk. However, SCORE
significantly overestimated the observed fatal CVD events in our cohort (SIR: 0.43) QRISK2
also substantially overestimated the observed risk of CVD in nearly all of the deciles (SIR:
0.60).
Reclassification of risk estimates
Scatter plot comparisons of the calculated risk of CVD by the developed risk calculators com-
pared to the calculated risk by FRS demonstrated that many of the new risk calculator values
were lower than the FRS values in the high risk centers and the majority of the new risk calcu-
lator values were lower than the FRS values in the low risk centers (Fig 3).
Reclassification was assessed separately for patients in the high and low CVD risk centers
(Table 7). In the high CVD risk centers, 46% of patients remained in the same CVD risk cate-
gory when classified by Model A as when classified by FRS, 36% of patients were classified into
a higher risk category by Model A than by FRS and 8% of patients were classified into a lower
risk category by Model A than by FRS. In the low CVD risk centers, 53% of patients remained
in the same CVD risk category when classified by Model A as when classified by FRS, only 2%
Table 3. Cardiovascular Disease (CVD) event rates by cohort (ordered by CVD event rate).
cohort n CVD events Mean length of follow-up (95% CI) Person-years of observation CVD event rate (%/ yr.)
Netherlands/Nijmegen 1049 147 7.8 (0.9, 12.0) 8226.5 1.8
Sweden 404 31 4.8 (1.8, 5.0) 1936.0 1.6
US/Olmsted 661 76 8.1 (0.7, 12.0) 5322.6 1.4
Netherlands/Enschede 585 22 3.0 (1.4, 3.5) 1741.8 1.3
US/BRASS 1090 65 4.9 (0.5, 10.1) 5380.4 1.2
Norway/EURIDISS-ORAreg 161 15 8.4 (3.4, 11.1) 1349.8 1.1
US/UCLA 147 4 2.7 (0.3, 3.4) 398.2 1.0
South Africa 191 8 5.2 (1.0, 10.6) 995.7 0.8
Greece 197 3 2.2 (1.0, 3.8) 427.6 0.7
Spain 509 5 1.6 (0.2, 2.7) 808.4 0.6
UK 313 10 5.9 (1.2, 7.3) 1844.6 0.5
Canada 186 2 5.0 (0.2, 11.8) 930.3 0.2
Mexico 145 1 5.4 (0.3, 9.6) 777.5 0.1
OVERALL 5638 389 5.3 (0.5, 12.0) 30139.3 1.3
Abbreviations: BRASS = Brigham and Women’s Rheumatoid Arthritis Sequential Study, UCLA = University of California Los Angeles
https://doi.org/10.1371/journal.pone.0174656.t003
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of patients were classified into a higher risk category by Model A than by FRS and 45% of
patients were classified into a lower risk category by Model A than by FRS. In both the high
and low risk centers, patients with20% CVD risk calculated by FRS who were classified to
10-<20% risk by Model A did not demonstrate substantially lower observed CVD rates (21.6%
for high risk centers and 19.9% for low risk centers), calling into question the accuracy of
reclassification to lower risk by Model A. The observed event rates in the other re-categorized
patients agreed with the new classification by Model A in most cases, but the confidence
Fig 1. Cardiovascular event rates by cohort. (A) unadjusted rates. (B) rates adjusted for cardiovascular
risk factors.
https://doi.org/10.1371/journal.pone.0174656.g001
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intervals were wide due to small numbers of patients with events in many categories. Reclassi-
fication was not examined for SCORE and QRISK2 due to their extremely poor calibration in
our cohort.
Discussion
Efforts to develop a specific CVD risk calculator for patients with RA yielded 2 potential mod-
els including RA disease characteristics, but neither demonstrated improved performance
compared to CVD risk calculators designed for use in the general population. While it is statis-
tically feasible to develop an RA specific CVD risk calculator by pooling resources from many
centers, its ability to optimize prediction of future CVD in this patient population is question-
able due to several challenges.
Population of interest
It is important that the data used to develop a risk calculator is representative of the patients
who will be assessed by the risk calculator. For this purpose, population-based data may be
preferred to ensure that the entire spectrum of CVD risk is represented in the data. Referral
bias can have an unpredictable impact on CVD risk rates. For example, patients with RA have
a high burden of disease that includes increased risks for multiple comorbidities, such as inter-
stitial lung disease, osteoporosis, infections, hematologic cancers, as well as psychosocial
impairments (e.g., fatigue, depression, and cognitive decline) [32]. Patients with RA referred
to a cardiologist for CVD risk assessment may encompass a broad spectrum including both
the high CVD risk patients with several traditional CVD risk factors and the patients whose
RA and other comorbidities are controlled well enough that they will not be overwhelmed by
information about their increased risk of CVD. Thus referral bias may lead to either over or
under estimation of the true CVD risk in patients with RA. We aimed to develop a trans-
Table 4. Assessment of rheumatoid arthritis disease characteristics in cardiovascular disease risk
score model. Each potential risk factor is added to a model including age, sex, current smoking, hypertension
and lipid ratio (total cholesterol: high density lipoprotein cholesterol).
Characteristic Hazard ratio (95% CI)
RF positivity 1.18 (0.94, 1.47)
ACPA positivity 0.98 (0.78, 1.23)
RF/ACPA positivity 1.14 (0.90, 1.45)
ESR (linear), per 10 mm/hr 1.03 (0.99, 1.08)
ESR (log-transformed) 1.05 (0.94, 1.19)
CRP (linear), per 10 mg/L 1.03 (0.99, 1.06)
CRP (log-transformed) 1.05 (0.98, 1.13)
DAS28ESR 1.13 (1.05, 1.22)
Swollen joint count 1.03 (1.01, 1.05)
Tender joint count 1.03 (1.02, 1.05)
Patient global VAS, per 10 mm 1.12 (1.06, 1.17)
Physician global VAS, per 10 mm 1.15 (1.05, 1.26)
RA disease duration, per 10 years 0.92 (0.82, 1.04)
HAQ (linear) 1.37 (1.14, 1.64)
Abbreviations: CI = confidence interval; RF = rheumatoid factor; ACPA = anti-citrullinated protein antibodies;
ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; DAS = disease activity score; VAS = visual
analog scale; HAQ = health assessment questionnaire disability index
https://doi.org/10.1371/journal.pone.0174656.t004
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Atlantic CVD risk calculator, which may have failed, among other factors, due to geographical
differences. The countries included in our cohort have different healthcare systems, with dif-
fering access to health care, which may lead to differences in CVD risk [33]. In fact, countries
with lower socioeconomic welfare tend to have delays in diagnosis of RA and stricter eligibility
criteria for biologic therapies [34]. This inequity in access to treatment may influence disease
activity levels, the ability to achieve remission and other long-term outcomes of patients with
RA [35]. However, additional biases may also be at play, as the CVD risk estimated in our low
CVD risk strata is substantially lower than the CVD event rates in the general population of
the countries of origin. Perhaps optimal treatment of CVD risk factors and/or the RA disease
activity with use of biologics and tight disease control resulting in remission has reduced the
CVD event rate in these cohorts. Alternatively, there could be ascertainment bias leading to
under-reporting of CVD events. Either way, it is unlikely that the low CVD event rates pre-
dicted by our risk calculator will provide accurate estimates of CVD risk for all patients with
RA in the countries that had very low CVD risk rates in our cohort, since our calculator re-
classified 45% of patient in the low risk centers to lower risk categories than the FRS calculator.
Table 5. Coefficients and hazard ratios of risk calculator models.
Variable Model A: Risk score with DAS Model B: Risk score with HAQ
Coefficient Hazard ratio p-value Coefficient Hazard ratio p-value
Age (per 10 years) 0.482 1.62 <0.001 0.473 1.60 <0.001
Sex (male) 0.479 1.61 <0.001 0.476 1.61 <0.001
Current smoking 0.416 1.52 0.002 0.419 1.52 0.005
Hypertension 0.531 1.70 <0.001 0.640 1.90 <0.001
TC:HDL lipid ratio 0.340 1.40 0.010 0.416 1.52 0.003
DAS28ESR 0.126 1.13 0.001
HAQ 0.313 1.37 <0.001
Baseline survival at 10 years*
High risk centers 0.921 0.916
Low risk centers 0.963 0.968
Abbreviations: TC = total cholesterol; HDL = high-density lipoprotein cholesterol; DAS = disease activity score; ESR = erythrocyte sedimentation rate;
HAQ = health assessment questionnaire disability index
*for age = 55.3, male = 0, current smoker = 0, hypertension = 0, TC: HDL = 2.17, DAS28ESR = 4.0, HAQ = 0.73
https://doi.org/10.1371/journal.pone.0174656.t005
Table 6. Performance of developed risk calculators compared with general CVD risk calculators.
Performance measure Model A** Model B** FRS ACC/AHA SCORE QRISK2
Discrimination
C statistic (95% CI) 0.70 (0.66–0.74) 0.71 (0.67–0.75) 0.71 (0.67–0.74) 0.72 (0.69–0.75) 0.70 (0.67–0.74) 0.72 (0.69–0.76)
Calibration
Decile-based test, p-value* 0.23 0.31 <0.001 <0.001 <0.001 <0.001
Standardized incidence ratio (95% CI) 0.83 (0.74–0.94) 0.83 (0.73–0.94) 1.04 (0.94–1.15) 1.02 (0.90, 1.16) 0.43 (0.30–0.60) 0.60 (0.54–0.67)
Abbreviations: CI = confidence interval, FRS = Framingham risk score, SCORE = Systematic COronary Risk Evaluation, ACC/AHA = American College of
Cardiology/American Heart Association
*Adaptation of Hosmer-Lemeshow test for use in survival analyses. A significant value indicates deviations between observed and predicted outcomes.
Models A and B tested with 8 instead of 9 degrees of freedom to account for evaluation in the dataset used to fit the model
**Model performance assessed using 10-fold cross validation to avoid over-optimism
https://doi.org/10.1371/journal.pone.0174656.t006
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Purpose of risk prediction
Many CVD risk calculators were designed to help determine which patients should receive
lipid-lowering therapies, such as statins [5]. Due to this goal, historic cohorts with data collec-
tion prior to the availability of statins are often used to develop the risk calculators. These
cohorts have the advantages of long follow-up and do not have any biases related to statin use.
However, the CVD event rates in these cohorts may not reflect current CVD event rates, as
there have been many advances in addition to statins that have improved CVD outcomes in
recent years [36]. Another option would be to use more contemporary data and exclude (i.e.,
censor) subjects at the time when statins were initiated, but this could equate to systematic
exclusion of higher risk patients, which would result in unrealistic CVD event rates. Our
Fig 2. Calibration plots: Observed versus predicted 10-year risk for Cardiovascular Disease (CVD) according to
deciles of predicted risk. (A) Model A, (B) Model B, (C) the Framingham risk score (FRS) and (D) the American College of
Cardiology/American Heart Association Pooled Cohort Equation (ACC/AHA). The vertical lines are 95% confidence
intervals for the observed CVD risk estimates.
https://doi.org/10.1371/journal.pone.0174656.g002
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Fig 3. Comparison of the developed risk calculators (Model A and Model B) to the Framingham Risk Score (FRS). (A) Comparing Model A and
FRS for patients in the high cardiovascular risk strata. (B) Comparing Model A and FRS for patients in the low cardiovascular risk strata. (C) Comparing
Model B and FRS for patients in the high cardiovascular risk strata. (D) Comparing Model B and FRS for patients in the low cardiovascular risk strata. In
each panel, the dashed line represents identity and the solid line is a smoother line of trend.
https://doi.org/10.1371/journal.pone.0174656.g003
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pooled cohort includes data from after the introduction of statins, but we did not make any
adjustments for use of statins during follow-up, as these data were not available in all cohorts.
Study design
Another important consideration is the study design. Longitudinal cohort studies and regis-
tries are most often used for developing risk calculators for long-term outcomes. These obser-
vational studies are a more practical and cost-effective way to obtain long-term follow-up than
randomized clinical trials. However, observational studies suffer from confounding that can
be difficult or impossible to address. For example, event rates from the past may not apply to
contemporary patients due to changes in treatments, medical care or patient characteristics
(e.g., obesity). Another source of confounding in observational studies is confounding by indi-
cation. In patients with RA, those with more severe disease are more likely to receive biologics.
If biologics have an impact on CVD risk, this could bias the results of CVD risk assessment in
patients with RA. The alternative to observational studies is randomized clinical trials. While
randomized trials have the advantage of reducing confounding, they also have limitations.
Importantly, patients with comorbidities are often excluded in randomized trials, so the trial
population is unlikely to be representative of the population of interest for CVD risk evaluation
in RA.
Table 7. Reclassification for centers with high and low CVD risk for Model A compared with Framingham Risk Score (FRS).
High CVD risk Centers Model A
<5% 5- <10% 10- <20%  20%
FRS <5% N w/o events 329 320 52 1
N w/ events 5 9 4 0
Observed 10 yr risk (95% CI) 2.5 (0.0, 5.3) 3.6 (1.2, 6.0) 9.8 (0.0, 19.1) 0.0
5- <10% N w/o events 15 241 289 35
N w/ events 0 9 22 7
Observed 10 yr risk (95% CI) 0.0 6.4 (1.3, 11.3) 12.1 (6.8, 17.1) 30.8 (7.8, 48.0)
10- <20% N w/o events 1 64 371 203
N w/ events 0 4 32 30
Observed 10 yr risk (95% CI) 0.0 9.1 (0.0, 18.5) 16.4 (10.2, 22.1) 26.1 (15.4, 35.6)
 20% N w/o events 0 3 107 424
N w/ events 0 0 12 108
Observed 10 yr risk (95% CI) 0.0 0.0 21.6 (7.3, 33.6) 36.5 (29.6, 42.7)
Low CVD risk Centers Model A
<5% 5- <10% 10- <20%  20%
FRS <5% N w/o events 414 19 0 0
N w/ events 1 1 0 0
Observed 10 yr risk (95% CI) 0.3 (0.0, 0.9) 5.0 (0.0, 14.1) 0.0 0.0
5- <10% N w/o events 163 176 12 0
N w/ events 1 7 2 0
Observed 10 yr risk (95% CI) 2.6 (0.0, 7.4) 6.3 (1.4, 11.0) 0.0 0.0
10- <20% N w/o events 29 247 139 2
N w/ events 2 9 3 0
Observed 10 yr risk (95% CI) 0.0 6.5 (1.9, 10.9) 13.8 (0.0, 33.7) 0.0
 20% N w/o events 0 52 173 67
N w/ events 0 0 9 7
Observed 10 yr risk (95% CI) 0.0 0.0 19.9 (3.5, 31.9) 25.4 (4.2, 41.9)
https://doi.org/10.1371/journal.pone.0174656.t007
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Risk factor selection
Risk calculators are predicated on the notion that multiple risk factors may interact to increase
the risk of developing a disease. Patients with modest increases in several risk factors may be at
an equivalent or higher risk of disease than patients with one highly elevated risk factor. There-
fore, clinical management decisions should account for the constellation of risk factors in
order to optimize preventive strategies. Traditional CVD risk factors include age, sex, hyper-
tension, hyperlipidemia, smoking and diabetes mellitus. Considerations for adding other risk
factors for calculation of total CVD risk include assessments of the incremental value with
regard to improvement in risk predictions, as well as the cost of recording of the risk factor in
terms of both money and patient and clinician time/effort. DAS28 and HAQ were both con-
sidered and included in the risk prediction models developed in our study. HAQ is obtained
from a short patient questionnaire, but DAS28 requires a professional joint assessment as well
as an inflammatory marker, which make it a bit more time-consuming and expensive to mea-
sure than many of the traditional CVD risk factors.
In addition, causality is important, as risk factors included in a risk calculator are assumed
to result in lower risk when they are improved. However, causality is difficult to prove except
in randomized clinical trials, which are currently lacking regarding preventive interventions
and CVD outcome in patients with RA. Yet promising results from post hoc analyses from 2
large randomized placebo controlled trials with hard CVD endpoints (the IDEAL and TNT tri-
als) showed that patients without and with inflammatory joint diseases, including patients
with RA, had comparable lipid lowering effects and reduction in CVD events after intensive
treatment with statins [37].
There is a lack of optimal biomarkers to track RA disease activity. RF and ACPA are mea-
sures of disease severity, not disease activity. ESR and CRP are markers of inflammation,
which correlate with disease activity. However, CRP has been shown to be a mediator, not a
cause, of CVD in Mendelian randomization studies [38]. Swollen and tender joint counts and
patient and physician global VAS are measures of disease activity, which have been incorpo-
rated into composite disease activity measures, such as the DAS28 and Clinical Disease Activ-
ity Index, although these measures are somewhat subjective [39, 40]. In addition, disease
activity fluctuates over time in patients with RA, so it may not be reasonable to expect a single
disease activity measure to accurately predict 10-year CVD risk. Indeed, cumulative measures
of disease activity have shown stronger associations with CVD risk than single measurements
among patients with RA [41, 42]. However, cumulative measures are impractical to implement
in a risk calculator due to the difficulties of ascertaining them in clinical practice. Therapies for
RA are also tempting to consider as risk factors for CVD in patients with RA, but their use is
confounded by indication in observational studies. High dose glucocorticoids are thought to
increase CVD risk, but low dose glucocorticoids may reduce CVD risk by controlling inflam-
mation [43]. Methotrexate and biologic response modifiers may also modulate the risk of
CVD, but causal associations have not been proven [44, 45]. These issues may partially explain
why our risk prediction models did not perform better than CVD risk calculators for the gen-
eral population, which do not incorporate RA-specific factors.
Sample size considerations
Risk calculator development requires a large dataset with a high number of events. Obtaining a
large sample size for a study of patients with RA can be difficult. Despite the fact that RA is one
of the more common rheumatologic diseases, its prevalence is only 1%. Single centers typically
have too few patients to develop risk calculators for patients with RA. However, pooling data
from multiple centers may have challenges. Retrospectively collected data is often used to
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avoid waiting for follow-up to accrue in a prospective study. Despite predefined variables it
may be difficult to ensure that study-specific factors (e.g., variable definitions, surveillance
methods, identification of subjects, participation rates, etc.) are similar across centers. Regis-
tries often include larger numbers of patients than single center studies and are thought to
be less heterogeneous due to standardized data collection procedures, but selection bias for
enrolled subjects is an important issue that is often ignored. Heterogeneity can make it difficult
or even impossible to develop a risk calculator depending on whether the sources of the het-
erogeneity can be adequately explained and counteracted or not. Our study found significant
heterogeneity between centers, which was addressed by including low and high risk strata in
our risk prediction models.
Performance assessment
The performance of a risk calculator requires assessment of both discrimination and calibra-
tion. Discrimination is correctly ranking patients from low to high risk. It is commonly
assessed using the area under the receiver operating characteristic curve, which is also known
as the c-statistic. The c-statistic has a small practical range from a minimum of 0.5 (i.e., no pre-
dictive ability) to a hypothetical maximum of about 0.88. This narrow range has led to criti-
cism of the c-statistic as a useful measure of the incremental value of new risk factors [46]. The
c-statistics of our models were not better than the c-statistics for the general population risk
calculators.
Calibration is accurately predicting the absolute risk level. It is often assessed using the Hos-
mer-Lemeshow goodness-of-fit test for binary outcomes or analogous variations for time-to-
event outcomes [10]. Van Calster et al define 4 levels of calibration including: 1) mean calibra-
tion (i.e., calibration-in-the-large; or simply that the average predicted risk is similar to the
average observed risk), 2) weak calibration (i.e., a calibration intercept of zero and a calibration
slope of one; or simply that there is no systematic over or under estimation of predicted risks),
3) moderate calibration (i.e., among patients with the same predicted risk, the observed risk
equals the predicted risk, so among patients with a 10% predicted risk, 10% will have an
observed event) and 4) strong calibration (i.e., predicted risks and observed event rates corre-
spond for every covariate pattern) [8]. Strong correlation is desirable but unrealistic and may
lead to overly complex models, so moderate calibration has been recommended. Graphical
assessments of calibration are often more useful than statistical tests [6]. While our risk predic-
tion models showed better calibration than for the general population risk calculators, this
could reflect the fact that re-calibration is often needed when applying a risk calculator to a dif-
ferent population and calibration is expected to be better in the cohort used to develop the
model than in other cohorts.
All risk calculators should be validated prior to adoption for clinical use. Validation can be
done internally or externally. Internal validation can be performed by dividing the original
cohort into derivation and test sets or by using cross-validation techniques. We used 10-fold
cross-validation to assess the performance of our risk calculator models, in order to avoid the
over-optimism associated with assessing a model in the same data that was used to develop it.
Unfortunately, this internal validation did not show improved performance of our models
compared to general population risk calculators.
The lack of improvement in CVD risk assessment demonstrated by our models is consistent
with the recent findings of Alemao et al that adding CRP to the FRS or QRISK2 did not
improve CVD risk assessment for patients with RA [47]. Similarly, the Reynolds risk score,
which includes CRP, did not demonstrate improved performance for CVD risk assessment
among patients with RA [2] Since the increased risk of CVD among patients with RA likely
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stems from the systemic inflammation that characterizes RA, adding an inflammatory marker
to a CVD risk calculator seems reasonable, but it has not proven to be effective. As mentioned
previously, this lack of improvement may stem from the inherent fluctuations in disease activ-
ity over time in patients with RA, so it may not be reasonable to expect a single disease activity
measure to accurately predict 10-year CVD risk. Alternatively, RA therapies may be altering
CVD risk. Since most patients with RA will change treatments several times during a 10 year
period, it could be difficult to accurately estimate 10-year CVD risk without knowing which
treatments the patient will receive in the future. Therefore, accurate assessment of CVD risk in
patients with RA is complex.
Conclusion
Our risk calculators did not demonstrate improved performance among patients with RA
compared to general population CVD risk calculators. There are many issues involved in
derivation of a risk calculator, which make development of a CVD risk calculator for use in
patients with RA particularly challenging. These challenges should be considered by others
who may attempt to make a CVD risk calculator for patients with RA and by those who seek
to develop risk calculators for other purposes in other patient populations. In addition to the
challenges in development of a risk calculator, there may be certain obstacles in implementa-
tion of such a calculator in clinical practice. A risk calculator that includes both cardiovascular
and rheumatologic factors might require coordinated care from both a rheumatologist and a
cardiologist or general practitioners to obtain all the measures needed to assess it, particularly
if joint counts were required. Even patient-reported measures like the HAQ require time for
calculation [48].
Finally, the true worth of a risk calculator depends on its ability to improve health out-
comes. However, few studies have been done in the general population to prove that the
use of a CVD risk calculator results in improved outcomes compared to single factor based
approaches, despite the fact that the utility of risk calculators is assumed by several treatment
guidelines for CVD risk prevention [5, 49, 50]. Among patients with RA, traditional CVD risk
factors cannot explain all of the increased risk for CVD. RA disease specific factors have also
been shown to play a role in the increased CVD risk, but it is not known whether optimal
control of inflammation and RA disease activity would reduce the risk of CVD to that of the
general population [51, 52]. Further research is needed to determine the best approaches to
mitigating the increased risk of CVD among patients with RA. Meanwhile, clinicians should
follow guidelines for CVD risk assessment in the general population and make sure that tradi-
tional CVD risk factors are optimally treated in their patients with RA.
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